We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Raf-1 Keeps Developing Blood Vessel Cells Grouped Together

By LabMedica International staff writers
Posted on 30 Jan 2012
The elegant interaction between two molecular signaling pathways is critical to the process by which new blood vessels are formed (sprouting angiogenesis), and drugs that interfere with this interaction are being evaluated as possible chemotherapeutic agents.

Investigators at the University of Vienna (Austria) and the Medical University of Vienna (Austria) used video microscopy of developing blood vessels in vitro to study the interaction between the enzymes Raf-1(rapidly accelerated fibrosarcoma protein) and Rok-alpha.

Raf-1 is a MAP (mitogen-activated protein) kinase kinase kinase (MAP3K), which functions downstream of the Ras family of membrane associated GTPases to which it binds directly. More...
Once activated, the cellular RAF1protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2, which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. Activated ERKs are effectors of cell physiology and play an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation, and cell migration.

Rok-alpha is a serine/threonine kinase that regulates cytokinesis, smooth muscle contraction, the formation of actin stress fibers and focal adhesions, and the activation of the c-fos serum response element.

New findings published in the December 29, 2011, online edition of the journal Developmental Cell revealed that that Raf-1 was an essential component of the angiogenesis regulatory network, and that its removal impaired endothelial cell cohesion, sprouting, and tumor-induced angiogenesis. Mechanistically, Raf-1 was recruited to VE-cadherin complexes by a mechanism involving the small G protein Rap1 and was required to bring the Rho effector Rok-alpha to emerging adherens junctions (sites of connection between cells). This Raf-1-mediated fine-tuning of Rok-alpha signaling allowed the activation of junctional myosin and the timely maturation of adherens junctions essential for maintaining cell cohesion during sprouting angiogenesis.

“The real breakthrough came when we were able to use video microscopy on the developing vessels in vitro,” explained first author Reiner Wimmer, a researcher at the University of Vienna. “We realized that the cells without Raf-1 were actively migrating, but only as single cells. They could not migrate in a group.”

Related Links:

University of Vienna
Medical University of Vienna


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.